Can a daily pill outperform chemo for advanced pancreatic cancer?
Yes. In this phase 3 trial, the oral drug daraxonrasib roughly doubled how long patients lived compared with chemotherapy. People taking the drug lived a median of 13.2 months, versus 6.7 months with standard chemo.
That difference matters enormously. Current therapies offer limited benefit for patients with previously treated metastatic pancreatic cancer. For patients who have run out of good options, that is a genuine breakthrough.
How does this drug work?
Most pancreatic cancers are driven by a faulty protein called RAS. Oncogenic RAS mutations are present in more than 90 percent of pancreatic ductal adenocarcinoma cases. Think of RAS as a stuck “on” switch that tells cancer cells to keep growing. For years, scientists struggled to make a drug that could block it. Daraxonrasib is a new kind of RAS(ON) inhibitor, meaning it targets RAS while it is in its active, GTP-bound state, and it acts on both mutant and normal RAS. By shutting off that signal, the drug aims to slow or stop the cancer’s growth. It comes as a pill taken by mouth, instead of an IV drip.
What the data show
The results were strong and clear. A total of 500 patients with previously treated metastatic pancreatic cancer took part, with 248 assigned to daraxonrasib and 252 to chemotherapy of the investigator’s choice. Those who received daraxonrasib lived a median of 13.2 months, nearly double the 6.7 months seen with chemotherapy in the overall population. The risk of death was cut by about 60 percent, with a hazard ratio of 0.40 and a p-value below 0.001, which means the result is highly unlikely to be due to chance.
The drug also slowed how fast the cancer grew. Median progression-free survival was 7.2 months with daraxonrasib and 3.6 months with chemotherapy in the overall population, with a hazard ratio of 0.49. Most of the patients in this trial, 91.8 percent, carried a RAS G12 mutation, and results in that group closely matched the overall numbers: median survival of 13.2 months versus 6.6 months, and median progression-free survival of 7.3 months versus 3.5 months with a hazard ratio of 0.45.
Side effects tell an interesting story. Adverse events after starting treatment occurred in every patient on daraxonrasib and in 97.7 percent of those on chemotherapy, so this is not a gentle drug. But grade 3 or higher events were less common with daraxonrasib, at 61.8 percent versus 69.6 percent. The starkest difference was in stopping treatment: 1.2 percent of patients quit daraxonrasib because of a treatment-related side effect, compared with 11.2 percent on chemotherapy.
Dr. Kumar’s Take
I find this trial genuinely exciting, and I do not say that often about pancreatic cancer. For most of my career, this disease has been a wall I keep running into. Doubling median survival with an oral drug is the kind of result oncologists have been waiting decades to see.
The discontinuation numbers deserve as much attention as the survival curve. Nearly every patient on this drug had some adverse event, but almost none of them had to stop taking it, while roughly one in nine chemotherapy patients did. In a disease where patients are frail and time is short, a treatment people can stay on is worth a great deal.
I want to stay grounded. Median survival of 13.2 months is a major step forward, but it is not a cure. This was an open-label trial in people who had already been treated, and I will want to see long-term follow-up and how the drug performs in everyday practice. Still, this is real progress, and progress here has been painfully rare.
Who benefits most
The study focused on people with metastatic pancreatic cancer that had already been treated. Metastatic means the cancer has spread beyond the pancreas to other parts of the body. These are patients who have typically already tried first-line chemotherapy and have very limited choices left. In that hard situation, a treatment that nearly doubles median survival is a big deal.
The trial enrolled mostly patients with RAS G12 mutations, at 91.8 percent of the group. The broader trial population also included patients with G13 or Q61 mutations and patients in whom no RAS mutation was identified, and the survival benefit in that overall population matched the benefit in the G12 group. Those non-G12 subgroups were small, so I would not lean on them yet.
Practical Takeaways
- If you or a loved one has metastatic pancreatic cancer, ask your oncologist whether RAS-targeting drugs like daraxonrasib are available, either approved or through a clinical trial.
- Ask whether your tumor has been tested for RAS mutations and which one, since nearly everyone in this trial carried a RAS G12 mutation.
- Remember this trial studied people whose cancer had already been treated, so the findings apply most directly to that later-line setting.
- Keep your expectations realistic and hopeful at the same time: this drug nearly doubled median survival but is not a cure, so it works best as part of an overall care plan.
Related Studies and Research
- Phase I trial of high-dose vitamin C with gemcitabine in pancreatic cancer
- High-dose intravenous vitamin C boosts chemo sensitivity in ovarian cancer
- Saccharomyces boulardii reduces side-effects in H. pylori triple therapy
- Status of oral rehydration therapy in Bangladesh: how widely is it used?
FAQs
What is daraxonrasib and how is it taken?
Daraxonrasib is a new type of cancer drug known as a RAS(ON) multiselective inhibitor. It works by blocking RAS, a faulty protein that drives the growth of most pancreatic cancers, while that protein is in its active, GTP-bound state, and it acts on both mutant and normal forms of RAS. Unlike chemotherapy, which is usually given through an IV, daraxonrasib is taken orally as a pill. Patients on it were far less likely to stop treatment because of side effects than patients on chemotherapy.
Does this drug only work for patients with RAS mutations?
The trial was designed around patients with RAS G12 mutations, and 91.8 percent of the 500 patients enrolled had one. The broader population also included patients with G13 or Q61 mutations and patients with no RAS mutation identified, and survival in that overall population matched the G12 result at 13.2 months versus 6.7 months, with the same hazard ratio of 0.40. Since the non-G12 patients made up a small slice of the trial, I would treat the drug as established in RAS G12 disease and consider the rest an open question.
Is pancreatic cancer usually this hard to treat?
Yes. Current therapies offer limited benefit for patients whose metastatic pancreatic cancer has already been treated once. That is exactly why this trial stands out.
Bottom Line
In a phase 3 trial of 500 patients with previously treated metastatic pancreatic cancer, the oral drug daraxonrasib nearly doubled median survival compared with chemotherapy, from 6.7 to 13.2 months, cutting the risk of death by roughly 60 percent with a hazard ratio of 0.40. It also extended median progression-free survival from 3.6 to 7.2 months. Serious side effects were somewhat less common than with chemotherapy, and only 1.2 percent of patients stopped the drug because of a treatment-related side effect versus 11.2 percent on chemotherapy. This is a major step forward for patients whose current therapies offer limited benefit, even if it is not yet a cure.
